Summary of findings ‐ ivacaftor vs placebo
QoL (CFQ‐R) Respiratory domain · adults and children with cystic fibrosis and with at least one G551D CFTR mutation
1 finding from 1 review
- Potentiators (specific therapies for class III and IV mutations) for cystic fibrosis 2019 · Cochrane Headline outcomes onlyno estimate extracted3 studies · 222 participantsModerate